The Board of Directors of Regeneron Pharmaceuticals, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
Contact the Board
You can contact Regeneron Pharmaceuticals, Inc.'s Board of Directors to provide comments, to report concerns, or to ask a question, at the following address.
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
You may submit your concern anonymously or confidentially by postal mail. You may also indicate whether you are a shareholder, customer, supplier, or other interested party.
Communications are distributed to the Board, or to any individual directors as appropriate, depending on the facts and circumstances outlined in the communication. In that regard, the Regeneron Pharmaceuticals, Inc. board of directors has requested that certain items which are unrelated to the duties and responsibilities of the board should be excluded, such as:
- Product complaints
- Product inquiries
- New product suggestions
- Resumes and other forms of job inquiries
- Business solicitations or advertisements
In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the provision that any communication that is filtered out must be made available to any non-management director upon request.
You may also communicate online with our Board of Directors as a group.
Please submit your question using the form below.
|Nov 12, 2019||Director||Other acquisition or disposition||--||--|
|Nov 12, 2019||Director||Open market or private sale of non-derivative or derivative security||4,500||$349.00|
|Nov 12, 2019||Director||Exercise or conversion of derivative security exempted pursuant to Rule 16b-3||4,500||--|
|Nov 12, 2019||Director||Exercise or conversion of derivative security exempted pursuant to Rule 16b-3||4,500||$273.67|
|Nov 12, 2019||Director||Bona fide gift||1,000||--|
|Nov 08, 2019||Director||Open market or private sale of non-derivative or derivative security||1,000||$340.44|
|Nov 08, 2019||EVP Research and Development||Open market or private sale of non-derivative or derivative security||200||$333.32|
|Nov 08, 2019||EVP Research and Development||Other acquisition or disposition||--||--|
|Nov 08, 2019||EVP Research and Development||Open market or private sale of non-derivative or derivative security||100||$330.56|
|Nov 08, 2019||EVP Research and Development||Open market or private sale of non-derivative or derivative security||300||$341.38|